Prestige Consumer Healthcare Inc.
Financials
Valuation Metrics
Prestige Consumer Healthcare Inc.'s Market Cap is $2.46B. At end of 2025 it was $2.95B. Ranked #1916 of 3,112 in US market (top 62%), #1206 of 1,667 on NYSE (top 72%), #116 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.46B | US#1,916/3,112 Sec#116/269 |
| Revenue | $1.09B | US#1,888/3,112 Sec#52/269 |
| Net Income | $190M | US#1,290/3,112 Sec#45/269 |
| Total Assets | $3.55B | US#1,671/3,112 Sec#39/269 |
| Net Assets | $1.89B | US#1,293/3,112 Sec#40/269 |
| Employees | 600 | US#1,339/3,112 Sec#46/269 |
| Value | ||
| P/E | 12.92x | US#505/3,112 Sec#20/269 |
| P/B | 1.30x | US#632/3,112 Sec#29/269 |
| PEG | 1.70x | US#1,005/3,112 Sec#35/269 |
| P/S | 2.26x | US#1,390/3,112 Sec#36/269 |
| EV/EBITDA | 10.39x | US#823/3,112 Sec#31/269 |
| FCF Yield | 10.34% | US#476/3,112 Sec#17/269 |
| Profitability | ||
| ROE | 10.08% | US#1,365/3,112 Sec#56/269 |
| ROA | 5.36% | US#944/3,112 Sec#51/269 |
| Op. Margin | 28.42% | US#508/3,112 Sec#24/269 |
| Revenue Growth | -5.10% | US#2,514/3,112 Sec#137/269 |
| Earnings Growth | 7.58% | US#1,210/3,112 Sec#39/269 |
| Financial Health | ||
| Debt Ratio | 87.95% | US#963/3,112 Sec#161/269 |
| Total Debt | $1.05B | US#1,459/3,112 Sec#43/269 |
| FCF | $254M | US#1,228/3,112 Sec#41/269 |
| Cash | $64M | US#2,469/3,112 Sec#210/269 |
| Current Ratio | 3.57x | US#650/3,112 Sec#178/269 |
| Net Debt/EBITDA | 2.96x | US#1,650/3,112 Sec#71/269 |
| Performance | ||
| 1Y Return | -29.58% | US#2,759/3,112 Sec#224/269 |
| 1M Return | 5.04% | US#950/3,112 Sec#39/269 |
| From 52W High | -31.07% | US#2,216/3,112 Sec#168/269 |
| 1Y MDD | -48.45% | US#2,346/3,112 Sec#181/269 |
| Trading | ||
| Volume | 702,531 shares | US#1,803/3,112 Sec#175/269 |
| Trading Value | $36M | US#1,590/3,112 Sec#105/269 |
| Per Share | ||
| EPS | $3.90 | US#802/3,112 Sec#21/269 |
| BPS | $38.21 | US#627/3,112 Sec#14/269 |
Company Info
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.